Pitocin is a prescription injectable medication containing oxytocin, used to induce or strengthen labor by stimulating uterine contractions. It is administered intravenously and manufactured by Endo USA, Inc. This information was generated using AI and is provided for informational and research purposes only.

🔗 Related Datasets

• Oxytocin — HealthData.Gov
• Oxycodone hydrochloride — HealthData.Gov
• Oxycodone hydrochloride — HealthData.Gov
• Oxycodone hydrochloride — HealthData.Gov
• Oxycodone hydrochloride — HealthData.Gov

The oxytocin market was valued at $1.52 billion in 2025 and is projected to reach $2.54 billion by 2034, growing at 5.8% CAGR.

Aggregated anonymized self-reports from PeptIQ users tracking Oxytocin.

The size of the Oxytocin Supplement market was valued at USD 90 million in 2023 and is projected to reach USD 153.25 million by 2032, with an expected CAGR of 7.9% during the forecast period.

Aggregated, self-reported Oxytocin doses, side-effect frequencies, and outcomes from pseudonymous PepTalk contributors. Unverified, educational only.

Analyze Oxytocin import export data with detailed shipment records, HS codes, importing countries, top buyers, suppliers, and global trade trends.

The table includes 257 products with the active ingredient Oxytocin.

Oxytocin Market size, share, and trend analysis indicates growth from USD 1.3 Billion in 2025 to USD 2.94 Billion by 2035, at a CAGR of 8.5%

CEP certificate for Oxytocin issued by EDQM. Includes certificate number CEP 2002-200 - Rev 05, status Valid, and country Latvia.

Oxytocin (OXT) (OT) - BioCentury Target Profiles for the biopharma industry

The dataset contains the files (DARE_Workfile, Empathy_Workfile) used for the analyses of the study published by Fragkaki and Cima (2019) in Psychoneuroendocrinology. The study examined the effect of oxytocin administration on empathy and emotion recognition in 100 male adolescents living in residential youth care facilities. The study had a randomized, double-blind, placebo-controlled, within-subject design. The study included 3 sessions: screening session and two experimental sessions. In the experimental sessions, the participants received oxytocin in one session and placebo in the other session and performed the same experimental tasks on empathy and emotion recognition 30 min after administration. The order of the sprays as well as the order of the tasks were randomized using computer randomization. We performed mixed modeling to examined the effect of oxytocin on the outcome variables. The file “Documentation-ReadMe” describes the trial information, methodology, and the variables included in the datasets. The file "icu_dutch" is the Dutch version of the Inventory of callous-unemotional traits, the file ctq_dutch" is the Dutch version of the Childhood trauma questionnaire", and the file "ades_dutch" is the Dutch version of the Adolescent dissociative experiences scale.

Insights on the Oxytocin Receptor Antagonists Market reveal a valuation of USD 484 Million in 2025, with projections reaching USD 997 Million by 2035 at a CAGR of 7.5%.

The neurohormone oxytocin regulates many aspects of physiology primarily by binding to its receptor, the oxytocin receptor. The oxytocin receptor gene (Oxtr) has been shown to have alternative transcripts in the mouse brain which may each have different biological functions or be used in specific contexts. A popular animal model for studying oxytocin-dependent social behaviors is the prairie vole, a biparental and monogamous rodent. Alternative transcriptional capacity of Oxtr in prairie voles is unknown. We used 5′ rapid amplification of cDNA ends to identify alternative Oxtr transcription start sites in prairie vole brain tissue and uterine tissue. We then validated expression of specific transcripts in fetal brains and assessed the impact of exogenous oxytocin administration in utero on offspring brain development. We identified seven distinct Oxtr transcripts, all of which are present in both brain and uterine tissue. We then demonstrated that maternal oxytocin administration alters expression of a specific subset of Oxtr transcripts and that these different transcripts are under unique epigenetic regulation, such that in the perinatal period only one of the alternative transcripts is associated with DNA methylation in the Oxtr promoter. These data establish the existence of multiple Oxtr transcripts in prairie vole brain and uterine tissue and implicate oxytocin in the regulation of alternative transcript expression. These data have significant implications for our understanding of null mutant models in both mice and voles and translation in human birth and behavior.

The implementation of an institutional oxytocin checklist did not affect expert assessment of the use of oxytocin in labor. Checklist is included within the publication's appendix.

SPM{T_[416.0]} - contrast 3: Group x Drug: BDD greater in Oxyt

Collection description

The present study assessed the effects of intranasal oxytocin on the neural basis of processing emotional faces in patients with body dysmorphic disorder (BDD). Twenty BDD patients and 22 matched healthy control participants participated in a randomized, double-blind placebo-controlled within-subject functional magnetic resonance imaging study. Following acute intranasal OXT (24 IU) or placebo administration, we examined group and OXT related differences in task-based amygdala activation and related functional connectivity in response to an emotional face-matching task of fearful, angry, disgusted, sad, surprised and happy faces.

Subject species

homo sapiens

Map type

T

Unthresholded map

Collection description

This collection includes unthresholded maps for all the analyses conducted in the study. Only the conjunction maps are presented thresholded at voxel level p=0.002.

Subject species

homo sapiens

Modality

fMRI-BOLD

Analysis level

group

Cognitive paradigm (task)

pleasantness rating task

Map type

T

Breastfeeding behaviors can significantly change mothers' physiological and psychological states. The hormone oxytocin may mediate breastfeeding and mothers' emotion recognition. This study examined the effects of endogenous oxytocin fluctuation via breastfeeding on emotion recognition in 51 primiparous mothers. Saliva oxytocin was assessed before and after the manipulation (breastfeeding or holding an infant), and emotion recognition tasks were conducted. Among mothers who breastfed daily, mothers with more increased levels of oxytocin after breastfeeding showed greater reduced negative recognition and enhanced positive recognition of adult facial expressions. These oxytocin functions accompanying breastfeeding may support continued nurturing behaviors and also affect the general social cognition of other adults beyond any specific effect on infants.

Oxytocin Closed-Loop Infusion Controller Market Outlook

As per our latest research, the global oxytocin closed-loop infusion controller market size reached USD 466 million in 2025, reflecting robust adoption across healthcare settings worldwide. The market is projected to grow at a CAGR of 9.1% from 2026 to 2034, reaching an estimated USD 1,022 million by 2034. This strong growth trajectory is primarily driven by the rising prevalence of labor complications, increasing focus on maternal safety, and the rapid integration of advanced automation technologies in obstetric care. Historical data from 2019 through 2024 confirms a consistent upward trend, with adoption accelerating as healthcare systems in both developed and developing economies modernize their labor and delivery infrastructure.

One of the primary growth factors for the oxytocin closed-loop infusion controller market is the escalating need for precise and personalized drug administration during childbirth. Oxytocin is a critical hormone used for labor induction and the management of postpartum hemorrhage, but its administration requires careful titration to avoid adverse outcomes such as uterine hyperstimulation and fetal distress. Closed-loop infusion controllers, which automatically adjust oxytocin dosage based on real-time feedback from physiological parameters, significantly reduce the risk of under- or over-dosing. The growing awareness among healthcare professionals about the importance of controlled oxytocin delivery, combined with the rising incidence of high-risk pregnancies, is fueling the adoption of these advanced infusion controllers globally. Moreover, the increasing number of births in both developed and developing regions is amplifying the demand for safe and efficient labor management solutions.

Technological advancement in infusion systems represents another significant driver propelling market growth. The integration of sensor-based technologies, artificial intelligence (AI), and machine learning algorithms has revolutionized the capabilities of oxytocin closed-loop infusion controllers. These innovations enable real-time monitoring and adaptive dosing, enhancing patient safety and clinical outcomes. Similar innovation patterns are visible in adjacent fields such as vasopressor infusion control, where closed-loop automation is redefining hemodynamic management. The trend toward digitalization in healthcare, coupled with the proliferation of smart hospitals and maternity clinics, is fostering the deployment of integrated and connected infusion systems. The adoption of AI-driven controllers is particularly notable, as they offer predictive analytics and decision support, further optimizing oxytocin administration and reducing the burden on clinical staff.

The global market is also witnessing favorable regulatory developments and policy initiatives that support the adoption of advanced maternal health technologies. Governments and healthcare organizations are increasingly prioritizing maternal and neonatal safety, leading to investments in modernizing labor and delivery units. Funding for research and development in obstetric care devices, along with the establishment of stringent safety standards, is facilitating the commercialization and acceptance of oxytocin closed-loop infusion controllers. Furthermore, collaborations between medical device manufacturers, research institutions, and healthcare providers are accelerating innovation and expanding the market reach of these controllers, especially in regions with high maternal mortality rates.

From a regional perspective, North America currently holds the largest share of the oxytocin closed-loop infusion controller market, driven by advanced healthcare infrastructure, high awareness levels, and supportive reimbursement policies. Europe follows closely, with significant adoption in countries such as Germany, the United Kingdom, and France. The Asia Pacific region is poised for the fastest growth, fueled by increasing healthcare investments, rising birth rates, and government initiatives to improve maternal he

Oxytocin (pg/mL) and cortisol (nM or nmol/L) serum concentrations * B = Baseline; Start of test battery = 45′post-oxytocin administration, 90′post-MDMA administration, 150′post-pindolol administration; End of test battery = 120′post-oxytocin administration (first dose), 165′post-MDMA administration, 225′ post-pindolol administration; Statistically significant treatment-placebo contrasts are flagged with an ‘a’, MDMA vs pindolol + MDMA contrasts with a ‘b’.

Vasopressin and oxytocin are members of the neurohypophyseal hormone family found in all mammalian species. They are present in high levels in the posterior pituitary. Oxytocin stimulates contraction of uterine smooth muscle, and stimulates milk secretion in response to suckling by inducing contraction of myoepithelial cells in the mammary gland. Clinically, it is used to induce labour and promote lactation.Oxytocin receptors are found in uterine smooth muscle, myoepithelial cells in the mammary gland, and in the pituitary. Activation of phosphoinositide metabolism is effected via a pertussis-toxin-insensitive G-protein, probably of the Gq/G11 class.